<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">
Go Back

Biodesix Closes Series D Financing - August 2012

Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC).  Funding will also support clinical validation studies, product development, and ongoing collaborations with a number of biotechnology and pharmaceutical companies.

About Biodesix

Biodesix is a fully integrated molecular diagnostics company advancing the development of products for personalized medicine. Biodesix developed, validated and commercialized VeriStrat®, a serum proteomic test currently available to help physicians guide therapy for patients with advanced non-small cell lung cancer.  Samples are processed in Biodesix’ CLIA –certified laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy.  Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies. For more information about Biodesix, please visit www.Biodesix.com.

Topics: biotechnology, blood-based cancer test, cancer diagnostics, personalized medicine, pharmaceutical, Press Releases, Series D financing, serum proteomic test, Veristrat, liquid biopsy, lung cancer, molecular diagnostic, Non-Small Cell Lung Cancer, NSCLC